


The Fund's objective is to produce a high and rising income.
| Name | % Net Assets | 
|---|---|
| Total | 4.7% | 
| Sanofi-Aventis | 4.0% | 
| ENI | 3.9% | 
| Roche | 3.6% | 
| OPAP | 3.5% | 
| Vivendi Universal | 3.5% | 
| Nestlé | 3.2% | 
| Telefonica | 3.0% | 
| Nokia | 2.9% | 
| Novartis | 2.7% | 
| Key | % Net Assets | 
|---|---|
| 4.7% | |
| 4.0% | |
| 3.9% | |
| 3.6% | |
| 83.8% | 
| Date | 08-Nov-2022 | 
|---|---|
| NAV | 85.02p | 
| Currency | GBP | 
| Change | 0.004p | 
| % | n/a | 
| YTD change | 85.02p | 
| YTD % | n/a | 
| Fund Inception | 08/05/2007 | 
|---|---|
| Fund Manager | Malcolm Millar | 
| TER | 1.81 (31-Oct-2013) | 
| Minimum Investment | |
|---|---|
| Initial | £500 | 
| Additional | n/a | 
| Savings | £100 | 
| Charges | |
|---|---|
| Initial | 5.25% | 
| Annual Mang't | 1.50% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| No risk data available. | |
You are here: research